Bold Reforms Needed for India’s Vaccine Industry To Boom - McKinsey
This article was originally published in PharmAsia News
Executive Summary
Pushed by an expanded immunization program and a steady flow of new generation vaccines, India’s vaccine industry could grow to $1.65 billion if projected scenarios unfold.
You may also be interested in...
As GSK, Merck Slash Rotavirus Vaccine Prices, Bharat Biotech Eyes Supplies At $1 Per Shot
MUMBAI - India's vaccines specialist Bharat Biotech is reshaping prices of life-saving vaccines with the announcement that it will make available its rotavirus vaccine at $1 per dose for government supplies once it clears Phase III trials. Bharat Biotech expects the product to be market-ready in the next three years
Merck Aims For Deep Dive Into India's Vaccines Market With RotaTeq Launch; May Bring In Many More
MUMBAI - New Jersey-headquartered Merck & Co's Indian affiliate MSD India is fanning out 150 trained medical representatives in 17 cities to promote a basket of three vaccines - a moderately aggressive measure as compared to a few other similar-sized companies having presence in the segment
As Pfizer-Wyeth Combine Eye Vaccines Business, Novartis, GSK, Sanofi-Aventis And Indian Companies Brace For The Challenge
MUMBAI - These may be early days for Pfizer and Wyeth to analyze growth strategies of their vaccines business in emerging markets like India, but existing players like GlaxoSmithKline, Merck, Novartis and a host of home-grown companies like Panacea Biotec, Serum Institute and Shantha Biotech already seem well positioned to accelerate their growth in the quickly emerging vaccines market